Eli Lilly has announced plans to construct a $6.5 billion facility in Houston, Texas, aimed at boosting the production of active pharmaceutical ingredients and manufacturing a highly anticipated weight-loss drug, orforglipron. This large-scale investment is expected to create around 4,000 jobs in the area. The company also revealed plans for a $5 billion production plant in Virginia, further emphasizing its commitment to expanding manufacturing capabilities in the United States.